[1]
|
A. K. Patel and K. K. Patel, “Future Implications: Compliance and Failure with Antiretroviral Treatment,” Journal of Post-Graduate Medicine, Vol. 52, No. 3, 2006, pp. 197-200.
|
[2]
|
T. Hawkinsm, “Appearance-Related Side Effects of HIV-1 Treatment,” Aids Patient Care and STDs, Vol. 20, No. 1, 2006, pp. 6-18. doi:10.1089/apc.2006.20.6
|
[3]
|
R. Power, H. L. Tate, S. M. McGill and C. Taylor, “A Qualitative Study of the Psychosocial Implications of Lipodystrophy Syndrome on HIV Positive Individuals,” Sexually Transmitted Infections, Vol. 4, No. 2, 2003, pp. 137-141. doi:10.1136/sti.79.2.137
|
[4]
|
I. B. Corless, K. M. Kirksey, J. Kemppainen, et al., “Lipodystrophy-Associated Symptoms and Medication Adherence in HIV-AIDS,” AIDS Patient Care and STDs, Vol. 19, No. 9, 2005, pp. 577-586.
doi:10.1089/apc.2005.19.577
|
[5]
|
N. R. Reynolds, J. L. Neidig, A. W. Wu, A. L. Gifford and W. C. Holmes, “Balancing Disfigurement and Fear of Disease Progression: Patient Perceptions of HIV Body Fat Redistribution,” AIDS Care, Vol. 18, No. 7, 2006, pp. 663-673. doi:10.1080/09540120500287051
|
[6]
|
D. Rogowska-Szadkowska, S. Chlabicz, M. A. Oltarzewska and J. Sawicka-Powierza, “Which Factors Hinder the Decision of Polish HIV-Positive Patients to Take Up Antiretroviral Therapy?” AIDS Care, Vol. 21, No. 3, 2009, pp. 280-283. doi:10.1080/09540120802241871
|
[7]
|
C. P. Santos, Y. X. Felipe, P. E. Braga, D. Ramos, R. O. Lima and A. C. Segurado, “Self-Perception of Body Changes in Persons Living with HIV/AIDS: Prevalence and Associated Factors,” AIDS, Vol. 19, 2005, pp. S14-21. doi:10.1097/01.aids.0000191485.92285.c7
|
[8]
|
A. Ammassari, A. Antinor, A. Cozzi-Lepri, et al., “Relationship between HAART Adherence and Adipose Tissue Alterations,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Vol. 31, 2002, pp. S140-144.
|
[9]
|
M. Oette, P. Juretzko, A. Kroidl, et al., “Lipodystrophy Syndrome and Self-Assessment of Well-Being and Physical Appearance in HIV-Positive Patients,” AIDS Patient Care and STDs, Vol. 16, No. 9, 2002, pp. 413-417.
doi:10.1089/108729102760330254
|
[10]
|
B. E. Berger, C. E. Ferrans and F. R. Lashley, “Measuring Stigma in People with HIV: Psychometric Assessment of the HIV Stigma Scale,” Research in Nursing & Health, Vol. 24, No. 6, 2001, p. 518.
doi:10.1002/nur.10011
|
[11]
|
B. Cribier, M. Mena, D. Rey, M. Partisani, V. Fabien, J. Lang, et al., “Nail Changes in Patients Infected with Human Immunodeficiency Virus: A Prospective Controlled Study,” Archive of Dermatology, Vol. 134, No. 10, 1998, pp. 1216-1220. doi:10.1001/archderm.134.10.1216
|
[12]
|
B. Fisher and L. Warner, “Cutaneous Manifestations of the Acquired Immunodeficiency Syndrome,” International Journal of Dermatology, Vol. 26, No. 6, 1987, pp. 615-630. doi:10.1111/j.1365-4362.1987.tb02267.x
|
[13]
|
A. P. Panwalker, “Nail Pigmentation in the Acquired Immunodeficiency Syndrome,” Annals of Internal Medicine, Vol. 107, No. 6, 1987, pp. 943-944.
|
[14]
|
P. Chandrasekar, “Nail Discoloration and Human Immunodeficiency Virus Infection,” American Journal of Medicine, Vol. 86, No. 4, 1989, pp. 506-507.
doi:10.1016/0002-9343(89)90365-3
|
[15]
|
PicSearch. Pictures of Longitudinal Melanonychia, 2011. http://www.picsearch.com/pictures/Health/Cutaneous%20conditions/Longitudinal%20melanonychia.html
|
[16]
|
K. J. Smith, H. G. Skelton, J. Yeager, R. Ledsky, W. McCarthy, D. Baxter, et al., “Cutaneous Findings in HIV-1-Positive Patients: A 42-Month Prospective Study, Military Medical Consortium for the Advancement of Retroviral Research,” Journal of the American Academy of Dermatology, Vol. 31, No. 5, 1994, pp. 746-754.
doi:10.1016/S0190-9622(94)70236-5
|
[17]
|
D. A. Glaser and K. Remlinger, “Blue Nails and Acquired Immunodeficiency Syndrome: Not Always Associated with Azidothymidine Use,” Cutis, Vol. 57, No. 4, 1996, pp. 243-244.
|
[18]
|
B. M. Piraccini, M. Iorizzo, A. Antonucci and A. Tosti, “Drug-I Induced Nail Abnormalities,” Expert Opinion on Drug Safety, No. 1, 2004, pp. 57-65.
doi:10.1517/14740338.3.1.57
|
[19]
|
E. Haneke and R. Baran, “Longitudinal Melanonychia,” Dermatologic Surgery, Vol. 27, No. 6, 2001, pp. 580-584.
doi:10.1111/j.1524-4725.2001.01916.x
|
[20]
|
R. Baran and P. Kechijian, “Longitudinal Melanonychia (Melanonychia Striata): Diagnosis and Management,” Journal of the American Academy of Dermatology, Vol. 21, No. 6, 1989, pp. 1165-1175.
doi:10.1016/S0190-9622(89)70324-8
|
[21]
|
A. Tosti, Piraccini, M. Bianca and D. C. De Farias, “Dealing with Melanonychia, Seminars in Cutaneous,” Medicine and Surgery, Vol. 28, No. 1, 2009, pp. 49-54.
|
[22]
|
A. Tosti, G. Gaddoni, P. A. Fanti, A. D’Antuono and F. Albertini, “Longitudinal Melanonychia Induced by 3’- Azidodeoxythymidine: Report of 9 Cases,” Dermatologica, Vol. 180, No. 4, 1990, pp. 217-220.
doi:10.1159/000248033
|
[23]
|
R. G. Greenberg and T. G. Berger, “Nail and Mucocutaneous Hyperpigmentation with Azidothymidine Therapy,” Journal of the American Academy of Dermatology, Vol. 22, No. 2, 1990, pp. 327-330.
doi:10.1016/0190-9622(90)70039-K
|
[24]
|
G. Rahav and S. Maayan, “Nail Pigmentation Associated with Zidovudine: A Review and Report of a Case,” Scandinavian Journal of Infectious Diseases, Vol. 24: No. 5, 1992, pp. 557-561. doi:10.3109/00365549209054640
|
[25]
|
J. Sahai, B. Conway, D. Cameron, G. Garber, “Zidovudine-Associated Hypertrichosis and Nail Pigmentation in an HIV-Infected Patient,” AIDS, Vol. 5, No. 1, 1991, pp. 1395-1396.
doi:10.1097/00002030-199111000-00025
|
[26]
|
H. Brannon, Fitzpatrick Classification Scale, 2008.
http://dermatology.about.com/od/cosmeticprocedure/a/fitzpatrick.htm.
|